Cargando…

Identification of a RAD52 Inhibitor Inducing Synthetic Lethality in BRCA2-Deficient Cancer Cells

The breast cancer susceptibility gene 1/2 (BRCA1/2) is frequently mutated in many malignant tumors, such as breast cancer and ovarian cancer. Studies have demonstrated that inhibition of RAD52 gene function in BRCA2-deficient cancer causes synthetic lethality, suggesting a potential application of R...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Qianye, Li, Yu, Sun, Rong, Li, Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118686/ https://www.ncbi.nlm.nih.gov/pubmed/33995041 http://dx.doi.org/10.3389/fphar.2021.637825

Ejemplares similares

Compound F779-0434 causes synthetic lethality in BRCA2-deficient cancer cells by disrupting RAD52–ssDNA association
por: Li, Jian, et al.
Publicado: (2018)

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
por: Sullivan-Reed, Katherine, et al.
Publicado: (2018)

RAD52: Paradigm of Synthetic Lethality and New Developments
por: Rossi, Matthew J., et al.
Publicado: (2021)

Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells
por: Tseng, Wei-Che, et al.
Publicado: (2021)

Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors
por: Huang, Fei, et al.
Publicado: (2016)

The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells
por: Hromas, Robert, et al.
Publicado: (2017)

Synthetic Lethal Activity of Benzophenanthridine Alkaloids From Zanthoxylum coco Against BRCA1-Deficient Cancer Cells
por: García, Iris A., et al.
Publicado: (2020)

RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies
por: Toma, Monika, et al.
Publicado: (2019)

Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency
por: Bajrami, Ilirjana, et al.
Publicado: (2021)

Novel Insights into RAD52’s Structure, Function, and Druggability for Synthetic Lethality and Innovative Anticancer Therapies
por: Balboni, Beatrice, et al.
Publicado: (2023)

The function of RAD52 N-terminal domain is essential for viability of BRCA-deficient cells
por: Hanamshet, Kritika, et al.
Publicado: (2020)

PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency
por: Noll, Aurélia, et al.
Publicado: (2016)

Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations
por: Gonzalez, R, et al.
Publicado: (1999)

Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
por: Martino, Julieta, et al.
Publicado: (2023)

Non-Recombinogenic Functions of Rad51, BRCA2, and Rad52 in DNA Damage Tolerance
por: Prado, Félix
Publicado: (2021)

Correction: Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
por: Martino, Julieta, et al.
Publicado: (2023)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
por: Du, Tingting, et al.
Publicado: (2022)

Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer
por: Wicha, Max S
Publicado: (2009)

RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2-deficient human acute myeloid leukemia
por: Xu, Yichuan, et al.
Publicado: (2020)

Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells
por: Hengel, Sarah R, et al.
Publicado: (2016)

Yeast Rad52 is a homodecamer and possesses BRCA2-like bipartite Rad51 binding modes
por: Deveryshetty, Jaigeeth, et al.
Publicado: (2023)

Identification of a Small Molecule Inhibitor of RAD52 by Structure-Based Selection
por: Sullivan, Katherine, et al.
Publicado: (2016)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
por: Zatreanu, Diana, et al.
Publicado: (2021)

MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers
por: Srinivasan, Gayathri, et al.
Publicado: (2019)

Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer
por: Ratz, Leonie, et al.
Publicado: (2022)

Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia
por: Oei, Arlene L., et al.
Publicado: (2017)

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
por: Baquero, Juan Miguel, et al.
Publicado: (2022)

Chemogenetic profiling identifies RAD17 as synthetically lethal with checkpoint kinase inhibition
por: Shen, John Paul, et al.
Publicado: (2015)

Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells
por: Zhang, Baoyuan, et al.
Publicado: (2020)

Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells
por: Turchick, Audrey, et al.
Publicado: (2019)

Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers
por: Hamid, Abdulaziz B., et al.
Publicado: (2022)

Interaction of yeast Rad51 and Rad52 relieves Rad52-mediated inhibition of de novo telomere addition
por: Epum, Esther A., et al.
Publicado: (2020)

RAD52 S346X variant reduces breast cancer risk in BRCA2 mutation carriers
por: Biswas, Kajal, et al.
Publicado: (2020)

EXP2SL: A Machine Learning Framework for Cell-Line-Specific Synthetic Lethality Prediction
por: Wan, Fangping, et al.
Publicado: (2020)

Nimbolide targets RNF114 to induce the trapping of PARP1 and synthetic lethality in BRCA-mutated cancer
por: Li, Peng, et al.
Publicado: (2023)

Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib
por: Bagnolini, Greta, et al.
Publicado: (2020)

Synthetic Lethal Targeting of Superoxide Dismutase 1 Selectively Kills RAD54B-Deficient Colorectal Cancer Cells
por: Sajesh, Babu V., et al.
Publicado: (2013)

Bringing Rad52 foci into focus
por: Thorpe, Peter H., et al.
Publicado: (2011)

RAD52: Viral Friend or Foe?
por: Hendrickson, Eric A.
Publicado: (2020)

Mechanisms of synthetic lethality between BRCA1/2 and 53BP1 deficiencies and DNA polymerase theta targeting
por: Ronson, George E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0oidfpk3f8u7rt2q8nfsh807m1